Summary

Asia Pacific Lancet and Pen Needles Market Research Report Information by Type (lancets and pen needles), Application (Insulin, Capillary Blood Sampling, Hormones, Glucose Like Peptide (GLP), Skin Testing, and Others), End Use (Hospitals & Clinics, Diagnostic Centers & Medical Institutions, Home Care & Home Diagnostics, Research & Academic Laboratories, and Others), by Region (China, India Japan, South Korea, Australia, and Rest of the Asia-Pacific) Forecast to 2032

Market Overview
Asia Pacific Lancet and Pen Needles Market is anticipated to register a healthy market expansion a CAGR of 11.13% during the review period. Lancets are single-use gadgets/devices for narrow blood testing used by professionals in healthcare services. Lancets are a necessary part of the sharp-injury aversion programs in hospitals, clinics, research centers, and physicians’ offices. Lancets are one of the widely used alternative devices to obtain blood samples. Lancets and pen needles are receiving global recognition and acceptance due to their several convenient characteristics which gives them an edge over the traditional methods for vein puncture. A pen needle consists of a hollow needle which is embedded in a plastic hub and attaches to injection pens. Pen needles are used in conjunction with injection pens to deliver injectable medications into the body.
The increasing incidences of diabetes across the Asia-Pacific region and strategic initiatives associated with pen needles by market players are the major factors driving the growth of the Asia-Pacific lancet and pen needles market. However, alternative technologies for drug delivery are expected to restrain the growth of the Asia-Pacific market. Nevertheless, the growing geriatric population in the Asia-Pacific region is anticipated to create lucrative opportunities for the market.
Market Segmentation
The Asia-Pacific lancet and pen needles market, based on type, has been segmented into lancets and pen needles.
The lancet and pen needles market, based on application, has been segmented into insulin, capillary blood sampling, hormones, glucose like peptide (GLP), skin testing, and others.
The lancet and pen needles market, based on end user, is divided into hospitals & clinics, diagnostic centers & medical institutions, home care & home diagnostics, research & academic laboratories, and others.
Based on country, the Asia-Pacific lancet and pen needle market has been segmented into, China, India Japan, South Korea, Australia, and Rest of the Asia-Pacific. China accounted for the largest market share in 2022. However, India is projected to grow at the highest CAGR during the forecast period.
Major Players
The key market players are Novo Nordisk A/S, Terumo Corporation, B. Braun SE, Nipro Corporation, Abbott, and Cardinal Health.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 15
2 MARKET INTRODUCTION 17
2.1 DEFINITION 17
2.2 SCOPE OF THE STUDY 17
2.3 RESEARCH OBJECTIVE 17
2.4 MARKET STRUCTURE 18
3 RESEARCH METHODOLOGY 19
3.1 OVERVIEW 19
3.2 DATA FLOW 21
3.2.1 DATA MINING PROCESS 21
3.3 PURCHASED DATABASE: 22
3.4 SECONDARY SOURCES: 23
3.4.1 SECONDARY RESEARCH DATA FLOW: 24
3.5 PRIMARY RESEARCH: 25
3.5.1 PRIMARY RESEARCH DATA FLOW: 26
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED 27
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 28
3.6.1 REVENUE ANALYSIS APPROACH 28
3.7 DATA FORECASTING 29
3.7.1 DATA FORECASTING TECHNIQUE 29
3.8 DATA MODELING 30
3.8.1 MICROECONOMIC FACTOR ANALYSIS: 30
3.8.2 DATA MODELING: 31
3.9 TEAMS AND ANALYST CONTRIBUTION 33
4 MARKET DYNAMICS 35
4.1 INTRODUCTION 35
4.2 DRIVERS 36
4.2.1 INCREASING INCIDENCES OF DIABETES ACROSS THE ASIA-PACIFIC REGION 36
4.2.2 STRATEGIC INITIATIVES ASSOCIATED WITH PEN NEEDLE IN BY MARKET PLAYERS 36
4.3 RESTRAINTS 38
4.3.1 ALTERNATIVE METHODS FOR DRUG DELIVERY 38

4.4 OPPORTUNITY 39
4.4.1 GROWING GERIATRIC POPULATION IN ASIA-PACIFIC REGION 39
5 MARKET FACTOR ANALYSIS 40
5.1 PORTER'S FIVE FORCES MODEL 40
5.1.1 THREAT OF NEW ENTRANTS 40
5.1.2 BARGAINING POWER OF SUPPLIERS 41
5.1.3 THREAT OF SUBSTITUTES 41
5.1.4 BARGAINING POWER OF BUYERS 41
5.1.5 INTENSITY OF RIVALRY 41
5.2 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LANCET AND PEN NEEDLES MARKET 42
6 ASIA-PACIFIC LANCET AND PEN NEEDLES MARKET, BY TYPE 44
6.1 OVERVIEW 44
6.2 LANCET 45
6.2.1 SAFETY LANCET 47
6.2.1.1 PUSH BUTTON SAFETY LANCET 48
6.2.1.2 PRESSURE ACTIVATED SAFETY LANCET 48
6.2.1.3 SIDE BUTTON SAFETY LANCET 49
6.2.2 REGULAR LANCET 49
6.3 PEN NEEDLES 50
6.3.1 STANDARD NEEDLES 51
6.3.2 SAFETY NEEDLES 52
7 ASIA-PACIFIC LANCET AND PEN NEEDLES MARKET, BY APPLICATION 53
7.1 OVERVIEW 53
7.2 INSULIN DELIVERY 55
7.3 CAPILLARY BLOOD SAMPLING 56
7.4 HORMONE DELIVERY 56
7.5 GLUCOSE LIKE PEPTIDE (GLP) DELIVERY 57
7.6 SKIN TESTING 57
7.7 OTHERS 58
8 ASIA-PACIFIC LANCET AND PEN NEEDLES MARKET, BY END USER 59
8.1 OVERVIEW 59
8.2 HOSPITALS & CLINICS 61
8.3 DIAGNOSTIC CENTERS 62
8.4 HOME CARE & HOME DIAGNOSTICS 62
8.5 RESEARCH & ACADEMIC LABORATORIES 63
9 ASIA-PACIFIC LANCET AND PEN NEEDLE MARKET, BY COUNTRY 64
9.1 OVERVIEW 64
9.2 ASIA-PACIFIC 64
9.2.1 CHINA 66
9.2.2 INDIA 68
9.2.3 JAPAN 70
9.2.4 AUSTRALIA 72
9.2.5 SOUTH KOREA 74
9.2.6 REST OF ASIA-PACIFIC 76
10 COMPETITIVE LANDSCAPE 80
10.1 INTRODUCTION 80
10.2 MARKET SHARE ANALYSIS, 2022 80
10.3 COMPETITOR DASHBOARD 81
10.4 PUBLIC PLAYERS STOCK SUMMARY 82
10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 82
11 COMPANY PROFILES 83
11.1 NOVO NORDISK A/S 83
11.1.1 COMPANY OVERVIEW 83
11.1.2 FINANCIAL OVERVIEW 84
11.1.3 PRODUCTS OFFERED 84
11.1.4 KEY DEVELOPMENTS 85
11.1.5 SWOT ANALYSIS 85
11.1.6 KEY STRATEGIES 86
11.2 TERUMO CORPORATION 87
11.2.1 COMPANY OVERVIEW 87
11.2.2 FINANCIAL OVERVIEW 88
11.2.3 PRODUCTS OFFERED 88
11.2.4 KEY DEVELOPMENTS 89
11.2.5 SWOT ANALYSIS 89
11.2.6 KEY STRATEGIES 89
11.3 PHOENIX HEALTHCARE SOLUTIONS, LLC 90
11.3.1 COMPANY OVERVIEW 90
11.3.2 FINANCIAL OVERVIEW 90
11.3.3 PRODUCTS OFFERED 90
11.3.4 KEY DEVELOPMENTS 90
11.3.5 KEY STRATEGIES 91
11.4 CARDINAL HEALTH 92
11.4.1 COMPANY OVERVIEW 92
11.4.2 FINANCIAL OVERVIEW 93
11.4.3 PRODUCTS OFFERED 93
11.4.4 KEY DEVELOPMENTS 94
11.4.5 SWOT ANALYSIS 94
11.4.6 KEY STRATEGIES 94
11.5 NANCHANG YILI MEDICAL INSTRUMENT CO., LTD 95
11.5.1 COMPANY OVERVIEW 95
11.5.2 FINANCIAL OVERVIEW 95
11.5.3 PRODUCTS OFFERED 95
11.5.4 KEY DEVELOPMENTS 96
11.5.5 KEY STRATEGY 96
11.6 ABBOTT 97
11.6.1 COMPANY OVERVIEW 97
11.6.2 FINANCIAL OVERVIEW 98
11.6.3 PRODUCTS OFFERED 98
11.6.4 KEY DEVELOPMENTS 99
11.6.5 SWOT ANALYSIS 99
11.6.6 KEY STRATEGIES 99
11.7 JIANGSU HUIDA MEDICAL INSTRUMENTS CO., LTD 100
11.7.1 COMPANY OVERVIEW 100
11.7.2 FINANCIAL OVERVIEW 100
11.7.3 PRODUCTS OFFERED 100
11.7.4 KEY DEVELOPMENTS 100
11.7.5 KEY STRATEGIES 101
11.8 B. BRAUN SE 102
11.8.1 COMPANY OVERVIEW 102
11.8.2 FINANCIAL OVERVIEW 103
11.8.3 PRODUCTS OFFERED 104
11.8.4 KEY DEVELOPMENTS 104
11.8.5 SWOT ANALYSIS 104
11.8.6 KEY STRATEGIES 105

11.9 NIPRO CORPORATION 106
11.9.1 COMPANY OVERVIEW 106
11.9.2 FINANCIAL OVERVIEW 107
11.9.3 PRODUCTS OFFERED 107
11.9.4 KEY DEVELOPMENTS 107
11.9.5 KEY STRATEGIES 108
11.10 ADVACARE PHARMA 109
11.10.1 COMPANY OVERVIEW 109
11.10.2 FINANCIAL OVERVIEW 109
11.10.3 PRODUCTS OFFERED 109
11.10.4 KEY DEVELOPMENTS 109
11.10.5 KEY STRATEGIES 110
12 DATA CITATIONS 111